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Abstract
Highly inbred mice of three strains (A/J, DBA/2J and C57BL/6J) were
tested in an activity task at 14, 21, or 28 days of age.

Ten minutes

prior to testing, mice received treatment of either saline, scopolamine
(0.5 or 1.0 mg/kg) or d-amphetamine (0.5, 1.0 or 5.0 mg/kg).

At 14 days

of age DBA mice exhibited higher levels of activity than either A or C57
mice.

However, the increase in activity in C57 was such that at 21 and

28 days no difference was observed relative to DBA mice, and activity
was higher than that of A mice. With respect to the drug treatments,
d-amphetamine (5.0 mg/kg) increased activity in all strains at 14 days and
28 days of age. At 21 days, only C57 exhibited lack of a significant
increase in activity.

Clearly, the system responsible for responsivity

to d-amphetamine (dopamine and norepinephrine) is mature at 14 days of age.
In contrast to d-amphetamine, a response to scopolamine was evident in DBA
at 21 days of age, and in C57 and A at 28 days of age.

These data were

taken to support a caudal-rostral gradient of brain development, with the
inhibitory cholinergic system developing more slowly than the excitatory
catecholamine system.

Moreover, there also appears to be strain-specific

differences in neuronal development.

The differential development of the

cholinergic system, together with potential differences in the ontogeny of
the catecholamine system, were suggested as being responsible for age
dependent variations in activity, as well as differential responsivity to
pharmacological agents which increase catecholamine activity.
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INTRODUCTION
There is little debate regarding the degree of maturity of the central
•v- •- »nervous system at birth.

While considerable organization and proliferation

of neurons occurs prenatally, very rapid growth and development of synaptic
junctions occur in cortical and subcortical areas in the rat and mouse
brain during the third and fourth postnatal weeks (Aghajanian & Bloom, 1967).
In addition, rapid dendritic growth in the mouse brain has been recorded
between 8 and 15 days postnatally (Himwich, 1970).

Similarly, the maturation

of neurotransmitter systems probably approximates the sequence of synaptic
development, since the storage and release of these endogenous chemicals are
directly related to presynaptic functioning (Axelrod, 1970).

Indeed, Keller,

Bartholini, and Pletscher (1973) , Lander and Bloom (1974) , Loizou (1971),
and Loizou and Salt (1970) have identified increased levels of brain monoamines in close temporal proximity to the proliferation of axon terminals of
monoamine containing neurons.

Although most rapid ontogenesis of the central

nervous system occurs during the third and fourth postnatal weeks, further
development continues up to at least one year of age (Pscheidt & Himwich,
1966).

Of course, the precise nature of the growth is species dependent,

with precocial organisms such as the guinea pig (Bennett & Giarman, 1965)
and chick (Pscheidt & Himwich, 1966) showing greater prenatal development
than that seen in altricial organisms such as the rat (Eiduson, 1971).
Unlike the development of the peripheral nervous system, which follows
a proximo-distal and cephalo-caudal pattern, numerous studies have indicated
agreement with the Jacksonian model of brain organization (Jackson, 1931).

2

That is, there exists a caudal-rostral gradient of brain development with
the higher (rostral) regions developing more slowly than the lower (caudal)-•
regions-(Eiduson, 1971; Kim, Choi, Kim, Chang, Park, & Kang, 1970;
Moorcroft, 1971).

Moreover, it is well known that the rostral structures,

such as the limbic forebrain (including septum, hippocampus, and amygdala)
are largely modulated by acetylcholine which inhibits ongoing activity,
while caudal areas, such as hypothalamus, are exceptionally rich in
catecholamines (dopamine and norepinephrine) which tend to have excitatory
effects.

Areas between these structures, such as the caudate-putamen,

contain large amounts of both acetylcholine and dopamine (Cooper, Bloom,
& Roth, 1970).

In effect, the suggestion has been that the inhibitory

cholinergic system may interact, either in an additive or synergistic
manner, with the excitatory catecholaminergic system (Campbell & Mabry,
1973; Carlton, 1963, 1969; Feigley, 1974; Moorcroft, Lytle, & Campbell,
1971).
With respect to the development of the neurotransmitter systems, several
researchers have documented the slower development of cholinergic pathways
than of pathways involving catecholamines, with particular reference to
norepinephrine.

These observations have come primarily from experiments

evaluating enzymatic activity associated with various transmitters in both
rats (Coyle & Axelrod, 1972a, 1972b; Loizou, 1971; McGeer, Fibiger, &
Wickson, 1971; Mellgren, 1973; Porcher & Heller, 1972) and mice (Baker,
Hoff, & Smith, 1973).

For example, it has been observed that levels of

monoamine oxidase (MAO), the enzyme which degrades monoamines (dopamine,
norepinephrine, and serotonin) intracellularly, dopamine-g-hydroxylase,
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the enzyme involved in the conversion of dopamine into norepinephrine
(Coyle & Axelrod, 1972a), as well as tyrosine hydroxylase, the rate
limiting step in the synthesis of catecholamines (Coyle & Axelrod, 1972b;
Porcher & Heller, 1972), increase during postnatal development (Baker &
Hoff, 1972; Coyle & Axelrod, 1971; Haber & Kamano, 1966; Iverson,
de Champlain, Glowinski, & Axelrod, 1967; Loizou & Salt, 1970; Robinson,
1968).

Of course, the presence and effectiveness of the various neuro-

transmitters is related to the functional maturity of these enzymes.
The presence of these enzymes appears in detectable quantities in the
rodent brain at 15 days of gestation.

In contrast, enzymes associated

with acetylcholine synthesis or degradation (choline acetyltransferase
and acetylcholinesterase, respectively) reach adult levels between 15
and 20 days of age postnatally (Hatcori & McGeer, 1971), clearly revealing
slower development than enzymes associated with the azdnes (McGeer et al,
1971; see also Ladinsky, Consolo, Peri, & Garattini, 1972).

While the

data regarding enzymatic ontogeny have been useful in elucidating neuronal
and neurochemical development, a number of studies have been reported which
demonstrate that responsivity to pharmacological treatments may similarly
lend themselves to ontogenic analysis of endogenous chemicals, as well
as their role in the maturation of behaviour (Campbell, Lytle, & Fibiger,
1969; Fibiger, Lytle, & Campbell, 1970; McGeer et al, 1971; Thornburg &
Moore, 1973).

This particular technique has three advantages over the

biochemical assays described, the first simply being that the research can
be carried out more quickly and efficiently.

Secondly, pharmacological

effects of various treatments can be evaluated concomitantly, and finally,
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interactions among various systems can be detected.

In the following

sections, investigations of this nature, together with their rationale, are
documented.
Behavioural Effects of Acetylcholine and Catecholamines
It has been reported by a number of investigators that modifications
of neurotransmitter levels by pharmacological manipulation have profound
effects on a number of behavioural measures.

For example, agents which

effectively decrease levels of acetylcholine, such as scopolamine and
atropine, tend to enhance active avoidance (Anisman, 1973; Anisman, 1974a;
Anisman & Kokkinidis, 1974; Bignami & Rosic, 1971; Bignami, Amorico,
Frontali, & Rosic, 1971; Carlton, 1962; Carlton & Markiewicz, 1971; Safer
& Allen, 1970) increase levels of general activity (Anisman, 1974b; Anisman,
Wahlsten, & Kokkinidis, 1974; Payne & Anderson, 1967; Schwartzbaum,
Ide-Johanson, & Belgrade, 1974), decrease passive avoidance (Feigley, 1974),
and eliminate or reduce habituation tendencies (Anisman, 1974b; Anisman
& Kokkinidis, 1974; Carlton, 1961; Carlton & Vogel, 1965).

The converse

is true of agents which increase levels of acetylcholine e.g. physostigmine
or pilocarpine (see, for example, Anisman, 1974; Bignami & Rosic, 1970;
Bignami, Rosic, Mickalek, Milosevic, & Gatti, 1974, in press).

Manipulations

of dopamine and norepinephrine have also been observed to modify behaviour.
Decreasing levels of these amines tends to disrupt avoidance and reduce
locomotor activity (Cooper, Grant, & Breese, 1973; Costa & Groppetti,
1970; Ellison & Bresler, 1973; Fibiger, Fibiger, & Zis, 1973; Herman,
Trzeciak, Chrusciel, Kmieciak-Kolada, Drybanski, & Sokola, 1971; Neill,
Boggan, & Grossman, 1974), while increases in catecholamine activity with
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drugs such as amphetamine (Goodman & Gillman, 1965) augment avoidance
performance and increase general activity (Anisman, 1974a; Axelrod, 1974;
Bindra & Baran, 1959; Bindra & Mendelson, 1963; Cole, 1967-; Grossman &
Scalfani, 1971; Rech & Stolk, 1970; Van Rossum, 1970; see reviews in
Costa & Garattini, 1971).

Moreover, over the past few years, advances

have been made in differentiating behavioural properties of dopamine and
norepinephrine.

For example, dopamine appears to be involved in producing

stereotypic behaviours (Anden, Srombom, & Svenson, 1973; Fog, Randrup,
& Pakkenberg, 1967,

Molander & Randrup, 1974; Randrup & Munkvad

1967, 1968, 1970) and in modulating activity levels (Maj, Grabowska,
& Mogilnicka, 1971; Thornburg & Moore, 1973; Ungerstedt, 1971, 1974).
Norepinephrine is also involved in moderating activity, but to a lesser
extent than that of dopamine (Dominic & Moore, 19 71; Rolinski & ScheelKruger, 1973), and is also involved in changes in activity levels with the
inception of stressors (Anisman & Cygan, 1974). %These conclusions are
based on numerous studies indicating that synthesis inhibition of dopamine
and norepinephrine, via a-methyltyrosine, completely abolishes the excitatory
effects of amphetamine. However, inhibition of norepinephrine, while
leaving dopamine synthesis intact, by bis-(4-methyl-l-homopiperazinylthiocarbonyl) disulphide (FLA-63), the inhibitor of dopamine-^-hydroxylase,
has lesser effects on increases in activity promoted by amphetamine
(Carlsson, 1970).

Some of the more recent positions have involved the

suggestion that dopamine, in fact, modulates activity levels; however, this
is dependent on the presence of adequate levels of norepinephrine (Carlsson,
1970).
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In light of the polar effects of cholinergic and noradrenergic drugs,
it has been suggested that a distinct balance exists between the catecholamine excitatory system (dopamine and norepinephrine) and the inhibitory
cholinergic system (Carlton, 1963, 1968, 1969; McGeer et al, 1971).
According to this hypothesis, there exists a cholinergic mechanism in
the brain that antagonizes a dopaminergic and/or noradrenergic system,
which is excitatory.

The notion that these 2 systems act in a specific

balance is strongly supported by studies involving drug interactions.
For example, it has been demonstrated that low, normally non-effective
doses of scopolamine can

augment the action of amphetamine in increasing

responses within an active avoidance situation (Carlton, 1961; Carlton
& Didamo, 1961).

Furthermore, it has been found that cholinomimetic

drugs, such as pilocarpine, decrease amphetamine induced psychomotor
excitation in rats (Carlton, 1961).

Evidence has been gathered which

would suggest that there is an interaction between peripheral epinephrine
effects and the central cholinergic and noradrenergic systems.

Specifically,

injections of scopolamine are able to prevent reductions in motor activity
and avoidance ordinarily elicited by epinephrine (Manto, 1967; Remington
& Anisman, 1974).
Summarizing then, there are ample data indicating that the cholinergic
system inhibits active behaviours while the catecholamine system activates
these behaviours.
manner.

Moreover, these systems act in a reciprocal antagonistic

Extension of these studies involving direct application of anti-

cholinergics to limbic structures (Abeelen, Smits, & Raaijmakers, 1970;
Abeelen, Gilissen, Hanssen & Lenders, 1971; Grossman, 1962, 1964; Grossman
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& Scalfani, 1971), or dopaminergic and noradrenergic agents to the substantia
nigra and hypothalamus, respectively (Fibiger et al, 1973; Grossman &
Scalfani, 1971) have yielded results comparable to those witnessed with
systemic injections.

Such studies have thus implicated these structures as

being involved in inhibitory or excitatory processes, and have clearly
shown the drug actions to be primarily of a central rather than a peripheral
nature.
Ontogeny of Behaviour: Pharmacological Manipulations
From a behavioural vantage, the available data have supported the
Jacksonian model of brain organization, and have also implicated
catecholamine and acetylcholine ontogeny as factors in modulating
age-dependent changes in behaviour.

For example, in precocial organisms

such as the guinea pig (Campbell & Mabry, 1972; Hirsrich, 1970; Karki,
Kuntzman, & Brodie, 1962) and chick (Campbell & Mabry, 1972; Masai,
Kusunoki & Ishibashi, 1965), where the brain is fairly well developed at
birth, little variation in activity levels is seen from 5 to 100 days of
age.

In contrast, among altricial organisms such as the rat (Moorcroft

et al, 1971) or hamster (Campbell & Mabry, 1972), a sizeable increase in
activity is observed between 10 and 15 days postpartum, followed by a
substantial decline in activity between 15 and 25 days of age.

It will be

recalled that these ages are roughly comparable to the caudal-rostral
pattern of brain development in which the inhibitory telencephalic centres
mature later than the brain stem excitatory areas. Surgical manipulation
of various brain structures have substantiated the role of limbic and
hypothalamic structures in the ontogenic variations in locomotor behaviour.

8

That is, surgical removal of the hippocampus, which appears to be a major
axis for acetylcholine activity (Kelsey & Grossman, 1969; Lewis, Shute, &
.,. JSilver, 1967; Lynch, Mathews, Mosko,.Parks & Cotman", 1972; Macadar, Roig,
Monti & Buddeli, 1970; Mellgren & Srebro, 1973), does not appear to affect
behaviour in the rat prior to 21 days of age, but produces marked increases
in activity among adult animals (Moorcroft, 1971).
In terms of responsivity to drug treatments, it has been observed
repeatedly that administration of amphetamine augments activity levels in
rats as early as 10 days of age, whereas scopolamine, which blocks cholinergic
action, is without effect until 20 days of age.

Moreover, these effects do

not appear to involve peripheral cholinergic action, since the quarternary
congener of scopolamine (i.e. methyl-scopolamine), which does not pass into
the brain, fails to affect activity levels (Anisman & Kokkinidis, 1974;
Campbell et al, 1969; Feigley, 1974).

In addition, benztropine, a potent

anticholinergic which resembles scopolamine both structurally and pharmacologically (Thornburg & Moore, 1973), produces similar results, suggesting
that the observed effects are not specific to scopolamine alone.

Confirma-

tion and extension of these results have come from additional studies by
Fibiger et al, (1970) , in which it was observed that the typical antagonism
of the amphetamine effects by pilocarpine ( a cholinomimetic) was not
apparent in rats younger than 20 days of age.

Similarly, the synergism

between d-amphetamine and scopolamine is not apparent at 10 days of age, but
is present in the 30-day-old rat (McGeer et al, 1970).

Clearly, it would

appear that a balance exists between the catecholaminergic and
cholinergic systems; however, the interaction between these transmitters
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is not in effect until adequate maturation of the cholinergic system has
taken place.
Greater specificity regarding catecholamine ontogenesis has come
recently from studies attempting to divorce the actions of the dopamine
and norepinephrine systems. Specifically, it has been reported (Lamprecht
& Coyle, 1972) that the norepinephrine system develops somewhat slower
than does the dopamine system.

Although the enzymes involved in the

conversion of dopa to dopamine (dopa decarboxylase) and dopamine to norepinephrine (dopamine-3-hydroxylase) progress equally quickly, the lag in
norepinephrine appears to be related to a deficiency of vesicular storage.
Further studies have suggested that both the norepinephrine and the dopamine
systems are mature at day one of age, but may possibly differ in terms of the
development of the receptor cells. Specifically, L-dopa, which increases
dopamine and norepinephrine activity, produces behavioural excitation as
early as one day following birth.

Similarly, clonidine, a norepinephrine

receptor stimulating agent, elicits a behavioural response similar to that
seen with L-dopa.

In contrast, responsivity to a dopamine receptor

stimulating agent,apomorphine, is not observed until 3-4 days postpartum.
Evidently, the production of both dopamine and norepinephrine differs by
only a small amount, but the age at which the receptors mature varies
by several days (Kellogg & Lundborg, 1972).

It may well be the case

that the catecholamine interaction with the forebrain cholinergic centres
may involve both dopamine and norepinephrine.

The precise specificity

as to which is predominant i.e. dopamine or norepinephrine, is not clear
since synthesis inhibition or depletion, as well as replenishment of
either transmitter, have comparable effects (Campbell & Mabry, 1973).
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Accordingly, both these amines may be equally important regarding potential
interaction with acetylcholine.

Summarizing then, the pharmacological

approach to the understanding of the ontogenesis of the nervous system has
yielded results comparable to that observed through autoradiographic
and histological methods. Of equal importance, these data have also
suggested that hyperactivity (or hyperreactivity) seen in immature animals
may well be due to retarded cholinergic development.

That is, when the

cholinergic system is functional, the excitatory effects of the catecholamine
system are dampened.

However, so long as the inhibitory cholinergic system

is not developed, activity levels are under control of the excitatory
catecholamine systems.

Thus, Campbell et al (1969) have postulated that

the rapid rise in activity levels between 10 and 20 days of age is due to
increased catecholamine activity, whereas the gradual decline in spontaneous
activity following 20 days of age is due to the development of the inhibitory
cholinergic system.

This notion is discussed in greater detail in the

following section.
Experimental-Clinical Implications
The concept of a noradrenergic-cholinergic model, with the noradrenergic
system maturing more rapidly than the cholinergic system presents a viable
framework for a theory of hyperactivity in the developing organism.

In

terms of human behaviour, it has been reported that severe hyperkinesis,
as defined by chronic excessive levels of motor activity (Werry, 1968), has
been estimated in at least 4% of all school-age children (Weiss, Minde,
Douglas, Werry, & Sikes, 1967).

This behavioural disorder has been

referred to by a number of names including "hyperkinetic behaviour disorder",
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"minimal brain dysfunction" (MBD), and "hyperactivity" (Grinspoon &
Singer, 1973).

The symptamology of the syndrome has been noted to include

extreme overactivity, distractibility, short attention span, impulsiveness,"
marked mood fluctuations, and aggression (Eisenberg, 1972).

The pharma-

cological and morphological evidence presented earlier on the differential
development of the two systems associated with the motor activity suggests
a possible link between biochemical development and the presence of a
hyperkinetic syndrome.

For example, the notion of delayed brain maturation

is compatible with the empirical observation that hyperkinesis tends to
improve with age (Millichap & Fowler, 1967).

As such, it may well be the

case that in the hyperkinetic child, there exists a retarded development
of the cholinergic system, or overactivity of the catecholamine system.
In fact, Wender (1974) has postulated that minimal brain dysfunction not
only involves monoamine disturbances, but also generic factors which may
be responsible for these aberrant levels of neurotransmitters.
One disconcerting finding regarding the hyperkinetic syndrome is that
administration of sympathomimetics such as amphetamine and ritalin, which
in non-hyperkinetic children increase motility, result in a diminution of
the hyperkinesis (Conners, 1970; Eisenberg, 1971; Millichap, 1968; Tec &
Levy, 1971).

Several possibilities exist which may account for the

paradoxical effects of sympathomimetics in the hyperkinetic child.
Specifically, where there exists an imbalance between noradrenergic and
cholinergic activity, further increases in catecholamine action may result
in a rebound involving yet a third system (e.g. serotonin) which inhibits
the catecholamine effects (Swonger & Rech, 1972).

Secondly, amphetamine
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may produce end-product-inhibition, thus resulting~in decreased synthesis of
dopamine and norepinephrine (Cooper et al, 1970).

Finally, amphetamine may

result in release of catecholamines frpm,storage granules^ thereby leaving
the organism with reduced levels of functionally effective amines (Welch
& Welch, 1970).

Such an effect would occur when utilization of amines

exceeds total biosynthesis.
Turning again to the animal literature, several findings have been
reported which are, in some respects, comparable to that seen in the
human hyperkinetic syndrome.

Specifically, it is well known that although

activity increases with amphetamine, the extent of the increase is
inversely proportional to baseline activity (Anisman et al, 1974; Fuller,
1970; Glick & Malloy, 1973; Mosser & Welch, 1973).

Yet, in the experiments

carried out to date, there has neither been a developmental approach to
hyperkinesis in animals, nor has there been an attempt to employ animals
exhibiting behaviour resembling hyperactivity.

To this end, the present

experiment represents an attempt to employ a possible animal analogue to
the hyperactive syndrome seen in the developing human.

For example, it

has been observed that the C57BL/6 strain of mice exhibit a relatively low
level of acetylcholine (Ebel, Hermetet, & Mandel, 1972; Pryor, Schlesinger,
& Calhoun, 1966), as well as exceptionally low cognitive abilities (Anisman,
1974e). Moreover, general activity is greater in C57 mice than in the DBA
strain, which in turn is greater than that of A mice (Anisman et al, 1974).
It follows that the increased levels of activity seen in the C57 strain
might be a function of low levels of acetylcholine and a related
ineffectiveness of the cholinergic inhibitory system.

Injections of an

anticholinergic, such as scopolamine, should result in increased levels of
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activity in those animals where large reductions in the system are possible,
but should be relatively ineffective in animals with already reduced
cholinergic levels.

This hypothesis has in fact been supported, in that

scopolamine has been shown to decrease levels of activity in the C57 strain
(Abeelen & Strijbosch, 1969; Abeelen et al, 1970, 1971; Anisman et al, 1974;
Oliverio, Eleftheriou, & Bailey, 1973).

In contrast, d-amphetamine, a

noradrenergic agent, uniformly increases activity levels in all three strains;
however, this increase is inversely related to baseline activity levels.
A second pint of interest in studies involving C57 mice is that this
strain undergoes what has been termed a "popcorn" stage of activity at
approximately 21 days of age (Anisman, unpublished observations; Wahlsten,
unpublished observations).

This period is evidenced by heightened loco-

motor activity and exaggerated reactions to novel stimuli, after which
activity decreases; furthermore, this increase coincides with increased
levels of norepinephrine in these animals (Schlesinger & Griek, 1970).
However, in other strains of mice (i.e. A and DBA), this rise in locomotor
activity is not observed, and they also exhibit lower levels of norepinephrine during this period of growth.

It may well be the case that the

"popcorn" stage of development is one in which the noradrenergic and
cholinergic systems are at greatest imbalance, thus leading to the observed
hyperkinesis. Accordingly, it may be possible to promote a retardation
of activity levels at this age via drugs which at other times in development
would augment motility.
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Given the apparent congruency between the human hyperkinetic syndrome
and that seen in mice, it would seem that a study involving genetic and
ontogenic variables in response to pharmacological treatments might be a
viable approach to the understanding of the etiology of human hyperkinesis.
The present study represents an attempt to further investigate the noradrenergic and cholinergic developmental sequence in three strains of mice.

Since

the noradrenergic and cholinergic mechanisms differ in their rate of
maturity (Campbell et al, 1960; Feigley, 1974; Fibiger et al, 1970),
examination of drug effects at different ages presents an opportunity to
determine whether observed increases in locomotor activity are a function
of increased noradrenergic levels or initial low levels of cholinergic
action.

Since amphetamine is known to act upon the noradrenergic system

(Houser & Van Hart, 1973; Javoy, Thierry, Kety, & Glowinski, 1968; Moore
& Lariviere, 1963; Schildkraut & Kety, 1967; Taylor & Snyder, 1970), it
is possible to administer such a drug at different ages postnatally to
evaluate the maturation of this system.

The use of the dextro-isomer of

amphetamine (d-amphetamine) rather than the levo-isomer (1-amphetamine)
is indicated by evidence that the former is a markedly more potent
excitator of norepinephrine, while the levo-isomer is equipotent to the
dextro-isomer in modifying dopamine action.

Behaviourally, it has been

shown that d-amphetamine is 10 times as potent as 1-amphetamine in enhancing
locomotor activity (Taylor & Snyder, 1970).

By the same token, scopolamine

can be used in a similar fashion to assess cholinergic development because
of its associated effects on the cholinergic mechanism.

For example, if

this system develops at different rates in the three strains, one should
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expect scopolamine to act only on those strains and at tho'se~particular
ages where the.cholinergic system is developed at the time_of drug
-administration (Campbell et al, 1969).

It is important to note that

different dosages of each drug are suggested by several findings.
Alhava and Mattila (1973), for example, report dose dependent differences
in catecholamine levels in the brain and heart of mice measured at three
ages postnatally following injection of amphetamine.

Similarly, in a

review of cholinergic actions, Carlton (1963) emphasizes the need of
yC

exeprimental evidence for different drugs in terms of a wider range of
dosages and a variety of behavioural tasks. In fact, Anisman et al,
(1974) have shown clear differences in dose response curves in different
strains of mice, probably owing to variations in endogenous levels of
acetylcholine, as well as in rate at which drugs are metabolized.
Finally, the drug and strain interactions are evaluated on general
locomotor activity.

This particular measure was employed because of

its sensitivity to pharmacological treatments.

Unlike tasks involving a

learning or memory component, drug effects are not inhibited by overriding
cognitive factors which are often observed in aversively or appetitively
motivated tasks (Anisman, 1974e;Longo, 1966).
Summarizing, in the present experiment, an attempt was made to (a)
outline the behavioural effects of d-amphetamine and scopolamine in three
strains of mice, (b) infer the ontogenesis of catecholamine and acetylcholine systems from the response to pharmacological treatments, (c)
evaluate strain-specific differences in the ontogeny of these two transmitter
systems, and finally (d) determine whether relationships exist between
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ontogenic and genetic variation in activity with the effectiveness of
pharmacological treatments.
The strains employed were^A/J, DBA/2J, and C57BL/6J mice.

These

strains were used because they represent a continuum of activity, with A
mice exhibiting lowest levels of activity as adults, while C57 shows the highest
levels of activity (Anisman et al, 1974).

Moreover, these strains also

show strain-specific variations in levels of acetylcholine and catecholamines.
Specifically, C57 exhibits the lowest levels of acetylcholine and A the
highest, whereas with respect to catecholamine activity, A mice exhibit low
turnover rates (Bovet & Oliverio, 1973).

Parenthetically, the within strain

variability in the development of various fiber tracts in these strains
is exceptionally small (Wahlsten, 1974a), as is the variation in response
to drug treatments (Bovet & Oliverio, 1973).

In face, it has been suggested

that the effects of scopolamine may be modulated by a single major gene (Sco)
(Oliverio et al, 1973).

Clearly, isogenic lines may be of great benefit

in evaluating drug effects owing to the relatively small variation seen in
the development of fibre tracts and transmitter systems. Mice were tested
at either 14, 21, or 28 days postpartum.

These ages were selected because

motor coordination is fairly well developed at these times (Wahlsten, 1974b),
and in addition, substantial data exists regarding catecholamine and
acetylcholine levels at these particular ages (Schlesinger & Griek, 1970).
Finally, the dosages of d-amphetamine and scopolamine employed were based
on earlier studies (Anisman & Cygan, 1974; Anisman & Kokkinidis, 1974;
Anisman et al, 1974), indicating that these were optimal levels.
Additionally, lower dosages than the optimal were also used in the event of
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the blood-brain-barrier being immature at these early ages; thus, extreme
dosage effects could be determined.

The design of the present experiment

was therefore a 3(strain) x 3(age) x 6(drug treatment) factorial in which
all factors were considered between groups.
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Method
Subjects
Subjects were 486 experimentally naive mice represented equally from
each of three highly inbred strains (A/J, DBA/2J and C57BL/6J).

Mice

were bred at the University of Waterloo from stock originally procured
from the Jackson Laboratory, Bar Harbor, Maine.

Females were removed

when visibly pregnant from their mating cages (16-18 days) and housed
individually.

Offspring were tested at 14, 21 or 28 days, having spent

their neonatal periods with the maternal parent. Entire litters were
tested on the same day in order to eliminate potential confounds owing to
removal of one or more offspring from the breeding cage and thereby
affecting the rest of the litter (Wahlsten, 1974).

Throughout the period

between birth and testing, ad libitum access to food, water and maternal
parent was available.
Apparatus
The testing apparatus consisted of a 21 x 21 x 30 cm. clear Plexiglas
chamber.

Photoelectric cells were situated on two walls 1.0 cm. above

the floor and spaced 7 cm. apart, thus forming a 3 x 3 matrix.
photobeam resulted in a count being recorded.

Crossing a

Once a beam was broken, this

particular cell could not be activated again until a second beam was broken,
thereby eliminating counts due to head bobbing or tremor. Activity counts
were recorded on a series of digital counters.
Procedure
At the appropriate age (14, 21 or 28 days), mice were individually
removed from the parent cage and treated with d-amphetamine sulphate
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,(0.5, 1.0, or 5.0 mg/kg), scopolamine hydrobromide (0.5 or 1.0 mg/kg)
or physiological saline (2 ml/kg) (n=9/cell).
v in

All drugs were dissolved

bacteriostatic water in a volume of 0.5 mg/ml.

Mice were placed in

a holding cage for a ten minute period, after which they- were put into
the test chamber for ten minutes.

During this time, activity was recorded.

Results
The number of photocell crossings were transformed through the
/x + 1

in order to reduce heterogeneity of variance.

The mean (± standard

error) of the transformed scores are depicted in Figure 1 as a function of
Strain, Age and Drug Treatment.

Analysis of variance of the transformed

Insert Figure 1 about here
activity scores yielded a significant Strain x Age x Drug Treatment interaction (F=3.79, df=20/432, p<.01) (see Appendix A, Table 1).

Subsequent

Newman Keuls multiple comparisons (a=.05) were carried out on the simple
main effects involved in this interaction, (see Appendix A, Table 3) the
only exception to this being the case of saline treated animals.

Inspection

of the data had revealed an exceptionally large means-variance relationship
which, owing to the extreme variance of amphetamine (5 mg/kg) groups, was
not significantly reduced through the transformation.

Indeed, the error

variance of the overall analysis was greatly inflated by the drug groups,
thus obscuring potential differences in saline animals whose activity
levels and variance were relatively low.

Accordingly, a separate analysis

of variance of the activity scores for the saline treated animals was
performed.

This analysis revealed a Strain x Age interaction (F = 6.23,

df = 4/72, p<.01) (see Appendix A, Table 2).

This particular finding was
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subsequently replicated (Anisman & Remington, unpublished- report).

In

any event, Newman Keuls multiple comparisons among the saline treated
animals revealed that in all three strains, activity was greater among
21- and 28-day-old mice than that witnessed in 14-day-old mice (see
Appendix A, Table 4).
three strains.

The actual level of increase varied across the

Specifically, at 14 days of age, DBA mice were significantly

more active than either A or C57 mice. The increase in C57 mice at 21
days of age was such that C57 did not differ from DBA, but both strains
exhibited activity levels which exceeded that seen in A mice. At 28 days
of age, a small but nonsignificant decline in activity was observed in DBA
and C57 mice, such that C57 levels of activity, but not DBA activity,
exceeded that observed in A mice. The decline in activity between 21 and 28
days of age is consistent with numerous other reports indicating that
activity reaches maximal levels at 21 days, after which a decline is noted
toward 28 days, when activity begins to resemble that seen in adult animals
(Campbell et al, 1969; Fibiger et al, 1970; Himwich, 1970; Mabry'& Campbell,
19 74; Moorcroft et al, 1971; Thornburg & Moore, 1973).

Indeed, among adult

mice, it is typically observed that C57 is considerably more active than
either DBA or A.

Thus, it is not unlikely that if activity had been

monitored at additional ages, the decline in activity would have been more
pronounced.
Turning to the effects of d-amphetamine and scopolamine, it was
observed that at the 5mg/kg dosage, d-amphetamine enhanced activity in
all strains as early as 14 days of age.

In DBA, this effect did not reach
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a significant value, as it did _in A and C57 mice. Nevertheless, effects
of d-amphetamine were maintained at 21 and at 28 days of age.

It is

interesting to note, though, that at 14 days of age, the most pronounced
amphetamine effect was seen in C57 mice, whereas at 21 and 28 days of age,
amphetamine has substantially greater effects in A mice than in DBA or
C57.

The latter drug effect is precisely the same as that observed in

adults of these strains. Evidently, although amphetamine alters activity
as early as 14 days postnatally, the response is not comparable to that of
adult levels. Quite possibly, maturation of the catecholamine system
continues after 14 days of age, or the effects of the drug are modified
with the maturation of ancillary systems which modify the effects of central
catecholamine agents (see, for example, Swonger & Rech, 1972).

A second

interesting finding here is that at 21 days of age, vhere C57 exhibits
maximal levels of activity, the response to amphetamine is at its lowest
level and does not reach statistical significance.

Essentially, such a

finding suggests that although the catecholamine system is intact (witness
the 14 day response to amphetamine), the effectiveness of amphetamine in
increasing activity is limited by developmental factors related to
endogenous catecholamine levels, turnover, degradation, or possibly involvement of a second antagonistic system.
The response to scopolamine was found to be very different from that
of amphetamine.

Specifically, at 14 days of age, scopolamine did not

increase activity in any of the strains.

In fact, a small but nonsignificant

decline in activity was seen in DBA mice. However, neither A or C57 mice
exhibited any change in behaviour in response to the drug treatment.

By
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21 days postnatally, a pronounced increase in activity was seen in response
to both doses of scopolamine with the DBA strain; in contrast, A and C57_
animals revealed smaller increases which failed to reach significance.
Finally, at 28 days of age, all three strains of mice exhibited increased
activity levels in response to scopolamine. Quite clearly, scopolamine
will exert disinhibitory effects on activity in all strains; however,
the appearance of these effects becomes apparent much later than the
amphetamine effect. In addition, the disinhibitory influence interacts
with strain in terms of the age at which disinhibition is observed.
It is important to note that the results presented in this paper
have dealt exclusively with general activity.

Additional data regarding

reaction to a startle stimulus i.e., air puff, have revealed precisely
comparable results (Remington and Anisman, unpublished report), suggesting
that the drug effects observed here deal with general activity and
reactivity.
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Discussion
Consistent with earlier reports (Anisman, 1974b,c; Anisman et al, 1974),
.strain differences in activity levels were observed; however, the present
data indicated that these strain differences interacted with age. At 14
days postnatally, C57 mice exhibited minimal levels of activity relative
to A and DBA mice. With increased development, the absolute rise in
activity of C57 mice was such that it exceeded that observed in A mice
and equalled that of DBA.

Together with other reports involving full

adult mice (Anisman, 1974; Anisman et al, 1974), it is apparent that
activity in the C57 strain surpasses that seen in DBA.
Recently, Oliverio et al (1973) have reported that activity levels,
although inherited in a polygenic fashion, are largely controlled by a
single autosomal gene (Exa).

The observed strain differences in activity

with age suggest either epistatic interaction, or a gene effect which
modulates behaviour only at later stages of development.

In as much as

activity also seems to involve neurochemical maturation (Campbell & Mabry,
1973; Carlton, 1963, 1969; Moorcroft et al, 1971), it may well be the case
that the gene in question involves adequate neuronal transmission and/or
maturation of enzymes associated with these transmitters.

Indeed, while

the effects exerted by this particular gene may be present, the manifestation of its behavioural consequences could be limited by differences in
morphological development.

For example, it is known that development

of different brain structures vary across inbred strains and their various
F^ and F£ hybrids (Wahlsten, 1974a, 1974b).

This work indicated differences

in development of areas associated with the limbic system, as well as
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differences in growth of up to 71 different fibre tracts including both
forebrain and hindbrain structures.
,,. Turning to, the drug effects observed in the present investigation, it
was observed that regardless of strain, a large increase in activity was
observed with administration of d-amphetamine.

This particular finding is

congruent with the many earlier reports indicating adequate and early
maturation of the hindbrain structures (Eiduson, 1971; Jackson, 1931;
Kim et al, 1970; Moorcroft, 1971).

Since d-amphetamine produces increased

synthesis, release, and reuptake of both dopamine and norepinephrine, it
is difficult to ascertain whether dopaminergic and noradrenergic structures
develop differentially.

Further analysis involving enzyme inhibitors such

as a-methyl-p-tyrosine or FLA-63 may thus be crucial for determining which
of these systems is in fact the more important one in mediating the early
effects of amphetamine (Kellogg & Lundborg, 1973).

Nevertheless, there

are substantial data indicating that dopamine, and possibly dopamine and
norepinephrine modulate the effects of d-amphetamine.

Thus, it would

appear safe to assume that the former of the two transmitters (and possibly
both) are necessary for the excitatory effects of amphetamine to become
apparent. However, the important point of the present investigation was
that the catecholamine system was sufficiently mature at 14 days of age to
allow for the drug effect to be apparent.
It is of interest to note that at 14 days of age, d-amphetamine appears
to have more potent effects on activity among C57 mice than among A or DBA
mice.

However, at 21 days of age, the full adult relationship is observed,

in that A mice exhibit a more pronounced response to amphetamine than DBA
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mice, which in turn exhibit a greater response than C57 mice (cf. Anisman,
1974c, 1974d).

Parenthetically, the response to d-amphetamine is apparently

-: not-due, to-.baseline levels of ..activity, since F^ hybrids revealing high
levels of activity, may exhibit large increments in activity with
amphetamine treatment, whereas a cross resulting in equally high levels
of activity may result in a small response to amphetamine.

Thus, the

actual effect of the drug is probably dependent upon neurotransmitter
synthesis, release, reuptake, and degradation. However, the behavioural
concomitants of the neurotransmitter status may be subject to interaction
with other inhibitory transmitter systems (cf. Anisman, 1974c).
In any event, the fact that highest levels of catecholamines in C57
are seen at 21 days of age (Schlesinger & Griek, 1970) , and that this
particular age is the one at which the smallest amphetamine effects are
observed, is consonant with the hyperactivity hypothesis posited earlier.
Namely, when the relations between catecholamines and acetylcholine are not
in balance, further increases in norepinephrine may result in a rebound
effect, or end-product-inhibition, thereby decreasing activity levels. In
as much as the amphetamine effect is apparent at 14 and 28 days, but
to a lesser degree at 21 days may well be due to the imbalance between
acetylcholine and catecholamines produced by the high levels of norepinephrine.

Specifically, at neither 14 or 28 days of age is the balance in

serious jeopardy, and consequently amphetamine augments activity levels.
With the imbalance at 21 days, a physiologically mediated system protects
the organism from further disturbances in the noradrenergic-cholinergic
balance, thereby decreasing the excitatory effects of dramphetamine. As
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already suggested, it is not clear what the form of this p-revention is, but
rebound effects or end-product-inhibition are not unlikely candidates.
Turning to the effects of scopolamine, it was observed^ that in none
of the strains was a behavioural change observed at 14 days postnatally.
At 21 days of age, only DBA mice exhibited increased levels of activity,
while at 28 days, scopolamine uniformly increased activity levels in all
three strains. Quite clearly, response to amphetamine is manifested much
earlier than to that of the anticholinergic, scopolamine.

This finding is

consistent with other reports indicating that manipulation of the noradrenergic system has profound effects on behaviour at an earlier age than alterations
of the cholinergic system.

Moreover, as the forebrain limbic structures are

primarily cholinergic and the hypothalamus and midbrain structures are
largely noradrenergic (Cooper et al, 1970), the temporal differences in the
effects of amphetamine and scopolamine provide evidence for the caudal-rostral
growth of the brain posited by Jackson (1931).

However, the very fact that a

differential response to scopolamine is noted across the three strains
suggests that there are strain differences in terms of brain development,
and in particular, cholinergic structures.
The notion that response to anticholinergics may be related to endogenous
levels of transmitters has been supported by research carried out in
several labs.

Specifically, in those instances where low levels of choline

acetyltransferase and acetylcholinesterase, two enzymes indicative of
acetylcholine levels, have been observed i.e. in the C57 strain (Ebel,
Hermetet, & Mandel, 1972; Mandel & Ebel, 1974), negligible responsivity to
anticholinergic agents has been reported (Abeelen & Strijbosch, 1969;
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-Abeelen et al, 1970, 1971;"Anisman et al, 1974; Oliverio et al, 1973).
Conversely, where higher levels of enzymes associated with acetylcholine
have been observed, as in DBA and A mice (Bovet & Oliverio, 1973; Mandel
& Ebel, 1974), substantial increases in activity were recorded following
treatment with scopolamine.

Thus, it is not an unlikely possibility that

a lack of response to scopolamine in immature animals simply reflects low
levels of acetylcholine. With the maturation of the cholinergic system,
the effectiveness of scopolamine in increasing activity becomes apparent.
Of particular importance here is the fact that in A and C57 mice, the
development of the cholinergic system is retarded to that of the DBA
strain.

Interestingly enough, although scopolamine has a pronounced

disinhibitory effect in C57 mice at 28 days of age, these effects are
eliminated or decline in adult animals suggesting further fluctuations of
cholinergic activity with progressive development.

In any event, it is

significant that in C57 mice, a very pronounced increase in activity is
observed between 14 and 21 days of age. This sizeable increase may well
be due to the lack of an inhibitory system at 21 days of age, together
with a very pronounced increase in levels of norepinephrine (Schlesinger
& Griek, 1970).

In effect, because of the gross imbalance between

catecholamine and acetylcholine levels, administration of amphetamine may
produce the apparently paradoxical effect of causing only minor increases
in activity.

In A mice, the cholinergic system is also not developed;

however, because the catecholamine levels are not changing as drastically
as in C57, the increase in general activity between 14 and 21 days of age
is a moderate one.

Furthermore, this notion may also account for the
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fact that amphetamine produces a pronounced increase in activity at 21
days of age in A mice.

Specifically, since norepinephrine levels are not

7 Aas high as in C57, the noradrenergic-cholinergic balance is not seriously
threatened, thus permitting the excitatory effects of amphetamine to become
apparent.

Moreover, with the development of the inhibitory cholinergic

system by 28 days, the excitatory effects of amphetamine are dampened
relative to that witnessed at 21 days of age.
It would seem reasonable that although catecholamine and acetylcholine
modifications both affect behaviour independently, these systems also act
in a coordinated fashion. As already suggested in earlier parts of this
paper, these two systems might interact in a homeostatic type of process,
whereby different excitatory and inhibitory systems antagonize each other.
Similarly, independent modifications of the two systems may result in an
additive, and even synergistic types of effects.

For example, cholinomimetics

such as pilocarpine have been found to reduce amphetamine induced excitation,
while anticholinergics such as scopolamine potentiate this arousal (Campbell
et al, 1969; Fibiger et al, 1970; Thornburg & Moore, 1973).

The reversal

appears to also be true, since administration of d-amphetamine results in
decreased levels of acetylcholine (Vasko, Domino, & Domino, 1974).
Moreover, these data also indicate that while a distinct balance exists
between the excitatory catecholamine and inhibitory cholinergic systems,
the cholinergic influence lags behind noradrenergic development during
ontogenesis, a finding in agreement with the present data.
While it is clear that the catecholamine and acetylcholine levels
modulate behaviour, it also seems to be the case that other putative
transmitters are also involved, either directly or indirectly, in the proposed
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balance model.- Suggestions have been made concerning"the jfole of the
noradrenergic system in interaction with the serotonergic pathways.
Specifically, para-chlorophenylalanine (p-CPA), a depletor~df"~brain
serotonin, interacts with amphetamine to increase activity levels in a
synergistic fashion, while administration of 5-hydroxytryptophan (5-HTP)
prevents this effect (Ellison & Bresler, 1974; Mabry & Campbell, 1973).
Developmentally, it is of interest to note that depletion of serotonin
by p-CPA fails to produce such synergistic effects with amphetamine at
10 days postnatally, although the effect is apparent by 15 days of age
(Mabry & Campbell, 1974).

Furthermore, lesions of the medial forebrain

bundle result in dramatic reductions in telencephalic content of serotonin
(60-84%), while at the same time producing a three-fold increase in amphetamine action (Green & Harvey, 1974).
In terms of dopaminergic pathways, it has been observed that dopamine
receptor blocking agents, such as haloperidol, inhibit amphetamine induced
increases in locomotor activity (Rolinski & Scheel-Kruger, 1973).

In

addition, both dopamine and norepinephrine appear to play a role in L-dopa
induced activity increases (Maj, et al, 1971).

Supporting the hypothesis

that dopaminergic pathways are integral to noradrenergic increases in
activity, are the findings that a-methyldopa, a substance which weakly
stimulates dopamine receptors but has profound effects on norepinephrine,
causes only slight increases in motor activity.

If, however, it is given

in combination with apomorphine, a dopamine receptor stimulating agent,
substantial increases in motor activity are recorded (Anden, et al, 1973).
Further evidence for the interaction of noradrenergic and dopaminergic
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pathways stems -f-rom-the-reeen-fe- literature on chemical lesions using
6-hydroxydopamine (6-0HDA).

Administration of this substance sharply

reduces brain levels of both norepinephrine and dopamine through
destruction of their respective transmitter pathways (Ungerstedt, 1971,
1974; Masuoka & Alcaraz, 1973; Fibiger, Phillips, & Zis, 1973; Richardson,
1974).

Following such lesions, L-dopa (the precursor of dopamine and

norepinephrine), in combination with FLA-63 (a blocking agent of norepinephrine synthesis), results in increased locomotor activity (Ahlenius,
1974).

Similarly, it has been reported that amphetamine-stimulated motor

activity and stereotyped behaviour are reduced following treatments which
decreased dopamine or dopamine and norepinephrine.

However, such

reductions are not seen in animals where only levels of brain norepinephrine
are reduced (Hollister, Breese, & Cooper, 1974).

Further investigations

support the hypothesis that dopamine and noradrenaline act in a combined
fashion in modulating spontaneous motor activity (Gordon & Shellenberger,
1973), as well as behaviours other than locomotion; for example, the
interaction of these neurotransmitters has been related to stereotyped
behaviours such as gnawing and continuous grooming (Molander & Randrup,
1974), in addition to alterations in body temperature (Caccia, Cecchetti,
Garattini, & Jori, 1973).
The complexity of these interactions does not end here. Just as
noradrenergic influences have been shown to interact with the cholinergic
system (Carlton, 1963, 1969; Campbell et al, 1969; Fengley, 1974; Fibiger
et al, 1970; Moorcroft et al, 1971; McGeer et al, 1971), it has been
indicated that dopaminergic effects influence, at least in part,
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acetylcholine.

Following administration of 6-0HDA, reductions in

"^ "

acetylcholinesterase, the degrading enzyme for acetylcholine, "have been
reported (Consolo, Ladinsky, Samanin, & Ghezzi, 1974; Grewaal,* Fibiger,
& McGeer, 1974; Kim, 1973).

In agreement with this data are findings that

6-0HDA lesions result in large increases in acetylcholine following administration of the drug (Grewaal et al, 1974; Kim, 1973).
Having observed these various interactions of neurotransmitter substances,
it would seem reasonable that any pharmacological explanation of behaviour
must involve a complex interaction of these various excitatory and
inhibitory systems.

In effect then, the suggestion here is that although

catecholamine and acetylcholine levels serve to modulate both genetic and
ontogenic variations in behaviour, other transmitter systems need to be
evaluated to elucidate their role in modifying behaviour.

With respect to

phenomena such as the hyperactive syndrome, it may veil be the case that
the aberrant behaviours observed are due, in part, to acetylcholine and
catecholamine imbalances, but in addition, other inhibitory systems such
as serotonin may also be poorly developed.

This is expecially important

since increased norepinephrine and/or dopamine excitation are extensively
magnified by decreases in serotonin (Ellison & Bresler, 1974; Green &
Harvey, 1974; Mabry & Campbell, 1973, 1974).

Thus, while variation in

response to amphetamine and scopolamine may be indicative of retarded
development, it is not sufficient to account for the entire hyperactive
syndrome.

Quite possibly, the hyperactivity and the inverse effects of

sympathomimetics may be more apparent in strains or individual organisms
suffering from a lag in serotonergic ontogeny.
currently underway.

Further work to this end is

Footnote
While a c e t y l c h o l i n e is t e c h n i c a l l y an e x c i t a t o r y
t r a n s m i t t e r in the sense that i t induces neuronal a c t i v i t y , i t

is

referred to as an i n h i b i t o r y t r a n s m i t t e r in the present document
since i t results in the reduction of ongoing locomotor behavior.
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Figure 1.

Mean transformed (i/x + 1) number of photocell crossings
(+ standard error of the mean) as a function of Strain,
Age and Drug Treatment.

•
EU
§§j
•

30-

saline
0.5 mg/kg
1.0mg/kg
5-0 mg/kg

JL,

20-

i

X

10

DBA
30

^

20

10

C57

z

<
U

30

20

10

s

amp

Rfcfo
scop

s

amp

DRUG
14

scop

s

amp

TREATMENT
21

AGE (days)

28

scop

APPENDIX A

Table 1
Analysis of Variance of Transformed Photocell Crossings (VX+1 )
as a Function of Strain, Age, and Drug Treatment

df

MS

F

2

770.62

42.61*

Age (A)

2

5714.7

315.99*

Drug (D)

5

1358.8

75.13*

S x A

4

121.16

6.70*

S x D

10

77.761

4.30*

A x D

10

249.68

13.81*

S xA x D

20

68.506

3.79*

Within Cells

432

18.085

Total

485

Between
Strain

* p

(S)

.01

53

Table 2
Analysis of Variance of Transformed Photocell Crossings (tfx+i)
for Saline Treated Animals as a Function of Strain and Age

Between

df

MS

F

2

104.01

10.05*

2

720.39

69.58*

4

64.499

6.23*

Within Cells

72

10.35

Total

80

Strain (S)
Age (A)
S x A

.01

_.

Table 3

.JJewman^Keuls multiple comparisons of simple main effects
on transformed scores ( /x+1 )

Sal: saline; A: amphetamine; S: scopolamine

A - 14 days

Drug Treatment

S(1.0)

S(1.0)

S(0.5)

A(0.5)

A(1.0)

Sal

A(5.0)

.01

.39

1.53

1.65

7.36*

.38

1.52

1.64

7.35*

1.14

1.26

_. 6.97*

S(0.5)
A(0.5)

.12

A(1.0)

5.83*
5.71*

Sal
A(5.0)

* p

nMS

.05
r=2

r=3

r=4

r=5

r=6

q.95

(r,432)

2.77

3.31

3.63

3.86

4.03

q.95

(r,432)

3.93

4.70

5.16

5.48

5.72

,_ -~=^. ^s=r-

Drug Treatment

A - 21 dayg

- *'~ Sal

Sal

A(0.5)
.32

A(0.5)

--A(l.O)-

A(5~.0)

S(0.5)

S(1.0)

3.72

4.65

4.78

24.73*

3.4

4.33

4.46

24.41*

.93

1.06

21.01*

.13

20.08*

A(1.0)
A(5.0)
S(0.5)

19.93*

S(1.0)

* p

.05

A - 28 days

Drug Treatment
A(l.O)
A(0.5)
Sal
S(l.O)
S(0.5)

A(0.5)

Sal

S(l.O)

S(0.5)

A(5.0)

1.3

3.44

8.80*

9.45*

15.78*

2.14

7.50*

8.15*

14.48*

5.36*

6.01*

12.34*

.65

6.98*
6.33*

A(5.0)

* p

A(1.0)

.05

5o

DBA - 14 days

Drug Treatment

S(0.5)

S(0.5)

S(l.O)

A(1.0)*

Sal

.89

4.73
3.84

S ( l . .0)
A(l. • 0)

A(0.5)

A(5.0)'

4.79

8.73*

8.81*

3.90

7.84*

7.92*

.06

4.0

4.08

3.94

4.02

Sal

'

A(0.5)

.08

A(5. 0)

* P

.05

DBA - 21 days

Drug Treatment
A(1.0)
A(0.5)
Sal
S(0.5)
S(1.0)

A(0.5)

Sal

S(0.5)

S(1.0)

A(5.0)

3.67

4.34

9.17*

9.93*

15.11*

.67

5.50*

8.19*

11.14*

4.83*

7.52*

10.77*

2.69

5.94
3.25

A(5.0)

* p

A(1.0)

.05

DBA - 28 days

Drug Treatment

A(l.O)

Sal

A(0.5)

A(5.0)

S(1.0)

S(075)-

2.60

2.78

9.88*

10.63*

10.77*

.18

7.28*

8.03*

8.17*

7.10*

7.85*

7.99*

A(5.0)

.75

.89

S(1.0)

———

.14

A(1.0)
Sal
A(0.5)

S(0.5)

* p

.05

C57 - 14 days

Drug Treatment

Sal

S(0.5)

A(0.5)

A(l.O)

A(5.0)

.15

.29

1.06

3.21

13.12*

.14

.91

3.06

12.97*

.77

2.92

12.83*

A(0.5)

2.15

12.06*

A(l.O)

_____

9.91*

S(l.O)
Sal
S(0.5)

A(5.0)

* p

.05

S(1.0)

C57 - 21 days

Drug Treatment

A(l.O)

A(1.0)

A(0.5)

Sal

S(1.0)

S(0.5)

A(5.0)

.92

2.30

2.98

3.45

6.95*

1.38

2.06

2.63

6.03*

.68

1.15

4.65

.47

3.97

A(0.5)
Sal
S(1.0)
S(0.5)

3.50

A(5.0)

* p

.05

C 5 7 - 28 days

Drug Treatment
A(1.0)
A(0.5)
Sal
S(1.0)
S(0.5)

A(0.5)

Sal

S(1.0)

S(0.5)

A(5.0)

3.99*

5.08*

10.22*

11.65*

12.57*

1.09

6.23*

7.66*

8.58*

5.14*

6.57*

7.49*

1.43

2.35
.92

A(5.0)

* p

A(1.0)

.05
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Table 4
Newman Keuls multiple comparisons on transformed
scores ( /X+t) for Saline Treated Animals

14 days

Strain

C57

C57

A

DBA

2.03

5.06*

A

3.83*

DBA

* p

.05

nMS

r=2

r=3

q.95 (r,432)

2.77

3.31

q.95 (r,432)

2.96

3.54

21 days

Strain
A
DBA

DBA

C57

4.76*

6.08*
1.32

C57

* P

A

.05

28 days

Strain :

.

,A

• »,

A

DBA

C57

2.34

5.21*

DBA

2.87

C57

.05

A strain

Age (days)
14
21

21

28

6.41*

6.47*
.06

28

* p

14

.05

o

DBA strain

Age (days)

14

14

21

28

4.98*

7.34*

21

2.36

28

* p

.05

C57 strain

Age (days)
14
28

28

21

13.71*

14.52*
.81

21

* p

14

.05

(
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Table 1
Total Number of Photocell Crossings for Individual Subjects
sa a Function of Age, Strain, and Drug Treatment

A - saline
14 days

21 days

28 days

0

215

37

23

86

37

35

161

137

56

39

139

0

72

166

6

133

30

0

14

139

15

129

138

12

117

141

A - amphetamine (0.5 mg/kg)
14 days

21 days

28 days

0

19

19

5

29

16

17

18

147

0

69

41

0

68

30

0

36

154

0

41

105

51

29

25

1

1

98

A -

28 days
61
52
27
84
24
117
53
18
2

A - amphetamine (5.0 mg/kg)
21 days
1316
850
879
1053
1152
571
899
826
668

65

A - scopolamine (0.5 mg/kg)
14 days

21 days

28 days

3

99

112

2

2

133

18

29

231

0

136

319

0

164

360

0

383

190

0

84

447

11

11

257

1

47

345

A - scopolamine (1.0 mg/kg)
14 days

21 days

28 days

0

78

172

15

18

164

8

230

152

0

29

183

2

533

286

0

123

298

0

79

253

6

23

499

0

71

186

66

DBA - saline
14 days

21 days

28 days

7

120

136

0

261

204

2

335

72

330

71

179

60

225

254

85

197

54

182

193

160

107

255

162

1

368

198

DBA - amphetamine (0.5 mg/kg)
14 days

21 days

28 days

79

318

61

23

259

395

243

252

223

292

211

53

35

114

121

7

61

224

419

392

97

403

92

296

30

186

86

DBA - amphetamine (1.0 mg/kg)
^

^

21 days

28 days

69

27

°

16

76

126

189

20

115

130

306

19

52

145

84

95

31

137

423

54

159

106

1

177
4
292
15

DBA - amphetamine (5.0 mg/kg)
14_davs

21 Days

28 days

H6

633

396

°

771

343

64

803

392

738

471

3

309
289

672

?6

561

690

105

413

633

262

695

568

371

588

152

68

"'-"-"--

DBA - scopolamine (0.5 mg/kg)

14 days"

21 days

28_days

0

507

91

2

39

679

1

565

42

10

192

727

0

153

598

50

522

467

0

612

623

1

614

500

24

591

475

DBA - scopolamine (1.0 mg/kg)
14 days

21 days

2

8 days

7 24

546

0

590

255

0

511

209

7

358

542

9

551

601

211

227

237

0

453

356

22

573

595

2

538

518

0

69

14 days

21 days

28 days

2

115

162

4

222

251

1

311

179

6

364

233

0

207

316

0

326

245

1

208

142

0

357

310

0

290

266

C57 - amphetamine (0.5mg/kg)
14 days

21 days

28 days

1

168

83

13

112

129

0

191

174

4

360

394

1

311

192

0

224

319

1

97

185

12

345

82

32

196

350

?0

C57 - amphetamine (1.0 mg/kg)
lJ4_daZs

21 days

28 days

3

108

H7

131

119

147

0

437

155

74

312

181

2

4

31

2

348

56

281

3

33

150

32

0

178

325

HI

C57 - amphetamine (5.0 mg/kg)
14 days

21 days

28 days

271

344

482

74

421

646

50

501

504

570

364

626

409

651

79

357

254

576

23

369

1161

231

417

490

141

581

402

?i

C57 - scopolamine (0.5 mg/kg)
14 days

21 days

28 days

3

345

221

2

264

500

2

250

563

1

219

541

0

64

531

4

269

647

1

372

418

2

638

422

1

392

485

C57 - scopolamine (1.0 mg/kg)
14 days

21 days

28 days

1

192

195

1

304

356

2

208

549

0

457

604

0

298

474

0

119

239

1

293

490

2

393

418

1

314

493

PRIMARY PATHWAY IN THE SYNTHESIS OF CATECHOLAMINES

Tyrosine

• (tyrosine hydroxylase)

(dopamine-B- hydoxylase)

*Dopa

^Norepinephrine

•(dopa decarboxylase)

• Dopamine

^(phenylethanolamine-N-methyl transferase)

»•

1»

Epinepherine.

Note: enzymes associated with oxidation or hydrolysis are indicated in brackets. Catecholamines are
degraded intracellularly by monoamine oxidase (MAO), and cxtracellularly by catechol-O-methyl transferase
(COMT).

(From Cooper, Bloom & Roth, 1 9 7 0 ) .
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LATER STAGES OF SYNTHESIS AND METABOLISM OF ACETYLCHOLINE

CITRATE

GLUCOSE

(From Cooper, Bloom & Roth, 1970)

